Diagnostics Development Launches Innovative Point-of-Care
Solutions. The new POCMATE™ platform delivers rapid, actionable clinical insights directly at the point of care, supporting earlier and more informed treatment decisions when every minute matters.
Read more about the
POCMATE™ Platform >
Advancing Precision Diagnostics in Infection Care
With antimicrobial resistance recognized as one of the world’s most pressing healthcare
challenges, accurate differentiation between bacterial and viral infections has become
essential for responsible antibiotic stewardship.
The new POCMATE™ BACT assay enables clinicians to rapidly distinguish between acute
bacterial and viral infections using either a venous or finger-prick blood sample, providing
results in approximately 10 minutes. By delivering timely diagnostic clarity, the assay has the
potential to reduce unnecessary antibiotic prescribing and support more targeted patient
management.
”Rapid and reliable identification of infection etiology is critical for improving patient outcomes
and combating antibiotic resistance,” said a spokesperson for Diagnostics Development
Sweden AB. ”POCMATE™ BACT provides healthcare professionals with actionable information
at the point of care, enabling faster and more confident treatment decisions.”
Read more about
POCMATE™ Bact >
A Novel Approach to Monitoring Sepsis Treatment Response
Sepsis remains one of the leading causes of mortality and healthcare expenditure worldwide,
yet clinicians continue to face significant challenges in evaluating treatment effectiveness
during the course of disease.
The newly launched POCMATE™ Sepsis assay offers a unique approach by reflecting the
biological response to antibiotic therapy in real time. The test provides healthcare
professionals with valuable insights into treatment efficiency and therapeutic success,
supporting personalized patient management and potentially improving outcomes in this life-
threatening condition.
”Current tools for monitoring sepsis treatment remain limited,” the company noted.
”POCMATE™ Sepsis introduces a novel capability to assess antibiotic effectiveness, helping
clinicians make better-informed decisions throughout the treatment journey.”
Read more about
POCMATE™ Sepsis >
Earlier Prediction of Acute Kidney Injury Risk
Organ dysfunction is a common and serious consequence of sepsis, with acute kidney injury
representing one of the most frequent complications. Early identification of patients at risk is
crucial for implementing preventive measures and optimizing care pathways.
POCMATE™ AKI has been developed to identify patients at increased risk of developing acute
kidney injury at an earlier stage of sepsis progression. By providing rapid risk assessment at the point of care, the assay aims to support proactive clinical intervention before irreversible organ damage occurs.
Read more about
POCMATE™ AKI >
